BiotechTube
Home/Starget Pharma/Michel Afargan, Ph.D.
MA

Michel Afargan, Ph.D.

Head of Drug Development

Starget Pharma

Therapeutic Areas

Oncology

Starget Pharma Pipeline

DrugIndicationPhase
DOTA‑PTR‑58SSTR3‑positive solid tumors (soft‑tissue, neuroendocrine, skin, liver)Preclinical

Leadership Team at Starget Pharma

SK
Sigal Kalmanson Cusnir
CEO
View full Starget Pharma profile